Nivolumab (Opdivo®) for advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma (1L). HTA ID: 21049

Assessment Status Awaiting response from Applicant
HTA ID 21049
Drug Nivolumab
Brand Opdivo®
Indication Nivolumab is indicated in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first line treatment of adult patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥5.
Assessment Process
Rapid review commissioned 01/11/2021
Rapid review completed 29/11/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 07/12/2021
Pre-submission consultation with Applicant 01/02/2022
Full submission received from Applicant 10/10/2022
Preliminary review sent to Applicant 27/03/2023